2200 Pennsylvania Avenue, NW
District of Columbia
We are a science and technology innovator committed to helping our customers solve complex challenges, and improving quality of life around the world.
A global family of more than 20 operating companies, we drive meaningful innovation in some of today’s most dynamic, growing industries. With operating companies based around the world—from California to Copenhagen—our groundbreaking businesses transform the fields of diagnostics, life sciences, dental care, and environmental and applied solutions by:
• improving patient health through powerful tools that increase diagnostic confidence
• advancing scientific research to illuminate the causes of disease and pave the way to new, life-saving treatments
• improving dental outcomes and patient care around the world
• ensuring the freshness, dosages and safety of food, pharmaceuticals and consumer goods
• protecting our global water supply and promoting environmental stewardship
We are a team of 59,000 dedicated associates who are Helping Realize Life’s Potential every day by bringing our diverse skills, backgrounds, and perspectives together to make a difference.
We are a diverse team of people and operating companies, each with unique missions and challenges. Yet, we are united by Our Shared Purpose, which directs how we live out every day to achieve our most ambitious goals.
Our Shared Purpose confirms our commitment to helping our customers achieve amazing things and the high standards by which we measure our own success. We innovate forward-looking technologies to solve our customers’ most complex challenges. We are their agents of possibility.
105 articles with Danaher
Danaher Corporation announced that Executive Vice President and Chief Financial Officer, Matt McGrew, will be presenting at the Goldman Sachs Global Healthcare Conference on Tuesday, June 8, 2021 at 2:10 p.m. ET.
Danaher Corporation announced that it has appointed A. Shane Sanders to its Board of Directors and to its Audit Committee.
Danaher Corporation announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Bank of America Healthcare Conference on Tuesday, May 11, 2021 at 2:00 p.m. ET.
DIVERSE SCIENTIFIC EXPERTISE AND PROPRIETARY INSIGHTS WILL SUPPORT COMPANY GROWTH AND IMPACT
Danaher Corporation (NYSE: DHR) (the "Company") announced today that it expects first quarter 2021 core revenue growth to be above the high-end of the Company's previously communicated guidance range. For the quarter ended April 2, 2021 , the Company expects revenue growth to be approximately 57.0% and non-GAAP core revenue growth
Danaher Corporation announced that Executive Vice President and Chief Financial Officer, Matt McGrew, will be presenting at the Barclays Global Healthcare Conference on Thursday, March 11, 2021 at 11:30 a.m. ET.
Danaher Corporation announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 10:50 a.m. ET.
Danaher Corporation (NYSE: DHR) announced today that Jose-Carlos ("JC") Gutierrez-Ramos has been named Senior Vice President and Chief Scientific Officer for Danaher. In this role, Dr. Gutierrez-Ramos will have responsibility for helping define Danaher's science and technology strategy across the organization, including facilitating i
Danaher Corporation announced that effective January 1, 2021, its Board of Directors has appointed Jennifer L. Honeycutt to the position of Executive Vice President of Danaher Corporation, with responsibility for the Company's Beckman Coulter Life Sciences, Integrated DNA Technologies, Leica Microsystems, Molecular Devices, Pall, Phenomenex, and SCIEX businesses.
Danaher Corporation announced a correction to the previously announced quarterly cash dividend payable on its 5.00% Series B Mandatory Convertible Preferred Stock.
Danaher Corporation announced results for the quarter ended July 3, 2020.
Danaher Announces Closing Of Common Stock Offering And Mandatory Convertible Preferred Stock Offering - May 12, 2020
Danaher Corporation announced that it has closed concurrent offerings of 9,509,203 shares of common stock at a price to the public of $163.00 per share and 1,717,500 shares of 5.00% Series B Mandatory Convertible Preferred Stock at a price to the public of $1,000 per share.
Danaher Corporation (NYSE:DHR) ("Danaher") announced today that it has commenced concurrent offerings of $1.25 billion of shares of common stock and $1.25 billion of shares of Series B Mandatory Convertible Preferred Stock, subject to market and other conditions (the offerings). Danaher expects to grant the underwriters separate 30-day o
Danaher Corporation announced results for the quarter ended April 3, 2020.
RAINER M. BLAIR TO SUCCEED THOMAS P. JOYCE, JR. AS PRESIDENT AND CEO IN SEPTEMBER 2020 [06-May-2020] WASHINGTON , May 6, 2020 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or "the Company") today announced that Executive Vice President, Rainer M. Blair , will succeed Thomas P. Joyce Jr. as President and Chief Executive Officer and as a member of the Co
Danaher Completes Sale Of Certain Businesses To Sartorius AG To Satisfy Regulatory Requirement For Cytiva Acquisition
Danaher Corporation (NYSE: DHR) ("Danaher") announced today it completed the sale of its label-free biomolecular characterization, chromatography hardware and resins, microcarriers and particle validation standards, single use tangential flow filtration systems, and stainless steel hollow fiber tangential flow filtration systems busines
Danaher Provides Update On First Quarter 2020 Financial Performance And Schedules First Quarter Earnings Conference Call
Danaher Corporation announced that for the quarter ended April 3, 2020 it expects revenue growth of approximately 3.0% and non-GAAP core revenue growth of approximately 4.5%.
Each series of new senior notes will have the same terms, other than issue date and issue price, as the outstanding senior notes, which Danaher issued on March 30, 2020.
GE announced the completion of the sale of its BioPharma business to Danaher Corporation for approximately $20 billion of net proceeds.
GE and Danaher Satisfy All Required Regulatory Clearances for BioPharma Transaction; Expect to Close on March 31, 2020
GE announced that, together with Danaher Corporation, it has entered into a consent decree agreement with the U.S. Federal Trade Commission in connection with GE’s definitive agreement to sell its BioPharma business to Danaher for approximately $20 billion of net proceeds.